Royal Bank of Canada’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$317M Buy
3,501,447
+1,054,448
+43% +$88.3M 0.05% 333
2026
Q1
$196M Buy
2,446,999
+375,801
+18% +$31M 0.03% 413
2025
Q4
$177M Sell
2,071,198
-291,987
-12% -$24M 0.03% 460
2025
Q3
$184M Sell
2,363,185
-873,662
-27% -$68.3M 0.03% 458
2025
Q2
$253M Buy
3,236,847
+1,265,508
+64% +$94.4M 0.05% 328
2025
Q1
$143M Sell
1,971,339
-316,342
-14% -$22.6M 0.03% 433
2024
Q4
$169M Buy
2,287,681
+315,968
+16% +$22.1M 0.03% 405
2024
Q3
$130M Sell
1,971,713
-491,970
-20% -$35.7M 0.03% 481
2024
Q2
$228M Sell
2,463,683
-257,649
-9% -$22.8M 0.05% 302
2024
Q1
$260M Buy
2,721,332
+59,249
+2% +$4.98M 0.06% 283
2023
Q4
$203M Sell
2,662,083
-1,334,940
-33% -$92.9M 0.05% 329
2023
Q3
$277M Sell
3,997,023
-698,748
-15% -$56.2M 0.08% 243
2023
Q2
$443M Buy
4,695,771
+226,787
+5% +$19.7M 0.12% 163
2023
Q1
$370M Sell
4,468,984
-348,205
-7% -$27.4M 0.1% 172
2022
Q4
$359M Sell
4,817,189
-37,343
-0.8% -$2.88M 0.1% 185
2022
Q3
$401M Sell
4,854,532
-434,004
-8% -$41.8M 0.13% 158
2022
Q2
$503M Sell
5,288,536
-833,153
-14% -$86.3M 0.15% 135
2022
Q1
$721M Sell
6,121,689
-379,528
-6% -$42.6M 0.18% 113
2021
Q4
$842M Sell
6,501,217
-13,588
-0.2% -$1.58M 0.19% 108
2021
Q3
$738M Sell
6,514,805
-8,160
-0.1% -$931K 0.19% 105
2021
Q2
$676M Buy
6,522,965
+445,786
+7% +$42M 0.18% 115
2021
Q1
$508M Sell
6,077,179
-697
-0% -$58.9K 0.15% 129
2020
Q4
$554M Buy
6,077,876
+43,762
+0.7% +$3.63M 0.16% 130
2020
Q3
$482M Buy
6,034,114
+825,011
+16% +$64.4M 0.17% 130
2020
Q2
$360M Buy
5,209,103
+226,697
+5% +$16.1M 0.14% 144
2020
Q1
$313M Buy
4,982,406
+541,932
+12% +$39.1M 0.15% 130
2019
Q4
$345M Sell
4,440,474
-433,956
-9% -$33.9M 0.12% 151
2019
Q3
$357M Sell
4,874,430
-78,090
-2% -$5.49M 0.14% 141
2019
Q2
$305M Buy
4,952,520
+331,491
+7% +$20M 0.12% 154
2019
Q1
$295M Buy
4,621,029
+238,170
+5% +$13.6M 0.13% 158
2018
Q4
$224M Sell
4,382,859
-252,828
-5% -$12.8M 0.11% 167
2018
Q3
$269M Buy
4,635,687
+130,119
+3% +$6.36M 0.11% 155
2018
Q2
$219M Sell
4,505,568
-145,563
-3% -$6.79M 0.1% 180
2018
Q1
$216M Buy
4,651,131
+387,108
+9% +$16.8M 0.1% 175
2017
Q4
$160M Buy
4,264,023
+294,831
+7% +$10.8M 0.07% 240
2017
Q3
$145M Buy
3,969,192
+9,648
+0.2% +$368K 0.07% 244
2017
Q2
$156M Buy
3,959,544
+26,838
+0.7% +$980K 0.08% 205
2017
Q1
$123M Buy
3,932,706
+426,747
+12% +$13.4M 0.07% 243
2016
Q4
$110M Buy
3,505,959
+64,008
+2% +$2.07M 0.06% 276
2016
Q3
$138M Buy
3,441,951
+1,674
+0% +$63K 0.08% 212
2016
Q2
$114M Sell
3,440,277
-97,809
-3% -$3.35M 0.07% 228
2016
Q1
$104M Buy
3,538,086
+154,857
+5% +$4.27M 0.06% 236
2015
Q4
$89.1M Buy
3,383,229
+2,085,225
+161% +$54.1M 0.06% 268
2015
Q3
$30.8M Buy
1,298,004
+418,800
+48% +$10.1M 0.02% 546
2015
Q2
$20.9M Buy
879,204
+42,408
+5% +$957K 0.01% 795
2015
Q1
$19.9M Sell
836,796
-119,304
-12% -$2.68M 0.01% 824
2014
Q4
$20.3M Buy
956,100
+280,170
+41% +$5.63M 0.01% 850
2014
Q3
$11.5M Buy
675,930
+245,262
+57% +$3.87M 0.01% 1122
2014
Q2
$6.16M Sell
430,668
-19,110
-4% -$259K ﹤0.01% 1501
2014
Q1
$5.56M Sell
449,778
-152,208
-25% -$1.76M ﹤0.01% 1487
2013
Q4
$6.6M Buy
601,986
+45,084
+8% +$508K ﹤0.01% 1466
2013
Q3
$6.46M Sell
556,902
-81,648
-13% -$955K 0.01% 1414
2013
Q2
$7.15M Buy
+638,550
New +$7.56M 0.01% 1225

Other funds holding EW

Royal Bank of Canada's EW Position: Q2 2026 in Review

Royal Bank of Canada increased its Edwards Lifesciences (EW) stake by 43% in Q2 2026, buying an estimated $88.3M and bringing the position to 3,501,447 shares worth $317M. The position accounts for 0.05% of the portfolio, ranked #333.

Royal Bank of Canada first reported a position in EW in Q2 2013 and has held it in 53 quarters since. The position peaked at $842M in Q4 2021. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Royal Bank of Canada held 3,501,447 shares of Edwards Lifesciences worth $317M as of Q2 2026.
  • Royal Bank of Canada bought 1,054,448 Edwards Lifesciences shares in Q2 2026, an estimated $88.3M.
  • Edwards Lifesciences made up 0.05% of Royal Bank of Canada's portfolio in Q2 2026, its #333 holding.
  • Royal Bank of Canada first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 53 quarters since.
  • Royal Bank of Canada's Edwards Lifesciences position peaked at $842M in Q4 2021.
  • 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.